Surface chemistry on nanoparticles governs their interactions with blood, tissues, and cells, and therefore determines biodistribution. Surface charge influences electrostatic attraction to cell membranes and plasma proteins; positively charged surfaces often show rapid uptake by endothelial cells and clearance organs, while neutral or slightly negative surfaces circulate longer. PEGylation and other hydrophilic coatings reduce protein adsorption and recognition by the reticuloendothelial system, prolonging circulation and increasing chances of reaching target sites. Omid Farokhzad at Brigham and Women's Hospital and Robert Langer at MIT have described how surface modifications are central to designing clinically useful drug carriers.
How surface charge and coatings shape distribution
The immediate formation of a protein corona after intravenous injection changes the nanoparticle “identity” seen by the body. Proteins that bind to the surface act as signals for macrophages in the liver and spleen, driving sequestration. Tuning surface chemistry to favor selective corona profiles can reduce off-target uptake. Active targeting ligands such as peptides or antibodies added to the surface can promote receptor-mediated uptake in diseased tissue, but their effectiveness depends on whether the ligand remains exposed after corona formation. Samir Mitragotri at Harvard University has emphasized that design must account for this dynamic interplay rather than assuming a static targeting moiety.
Biological, environmental, and social consequences
Consequences of altered biodistribution include changes in therapeutic index, unexpected toxicities from accumulation in liver or kidney, and reduced efficacy when insufficient drug reaches the intended site. In oncology, reliance on enhanced permeability and retention effects can vary across tumor types and patients, introducing territorial and cultural dimensions to clinical outcomes where access to personalized diagnostics differs. Environmentally, nanoparticles excreted after treatment can enter wastewater and impact aquatic systems; long-term ecological effects remain incompletely characterized, creating regulatory and public trust challenges. Clinically, populations with higher prevalence of liver disease or differences in immune function may experience distinct clearance patterns, requiring contextualized safety assessment.
Design strategies that modify surface hydrophobicity, charge, and ligand presentation remain the most practical levers to steer biodistribution. Evidence from translational research led by established investigators shows that predictable delivery arises from integrating surface chemistry with biological context, analytical measurement of corona formation, and careful preclinical models. Continued transparent reporting by research groups and regulatory oversight are essential to translate surface-engineered nanoparticles into safe, effective therapeutics accepted across diverse communities.